Grade My Investments
HomeFree Stock Grades › GKOS

Glaukos Corporation (GKOS) Stock Grade

GKOS · Healthcare

A+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$6.5B
P/E Ratio
Revenue Growth (YoY)
+32.3%
Net Margin
-37.0%
Return on Equity
Dividend Yield
None

About Glaukos Corporation's fundamentals

Glaukos Corporation is a $6.5 billion healthcare devices company experiencing strong revenue expansion at 32.3% year-over-year growth, indicating robust demand for its products. However, the company is currently unprofitable, with a net margin of -37.0%, and reported a net loss in its latest annual statement, meaning it is spending substantially more than it generates in revenue. The company does not pay a dividend, typical for growth-stage medical device firms that reinvest losses and cash into product development and market expansion.

Track GKOS free — no credit card required. Live grade + monthly AI report →